Nae-Gyu Kang

Dr. Nae-Gyu Kang

LG Household & Health Care Ltd.

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1997 in Nature
Verified
Journal Article
Closed access
PDF file
DKDaesoo Kim
Daesoo Kim
KJKi Sun Jun
Ki Sun Jun
SLSeong Beom Lee
Seong Beom Lee
NKNae-Gyu Kang
Nae-Gyu Kang
DMDo Sik Min
Do Sik Min
HSHee-Sup Shin
Hee-Sup Shin

23 August 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SKSeongsu Kang
Seongsu Kang
JSJi Eun Song
Ji Eun Song
SJSeung-Hyun Jun
Seung-Hyun Jun
SPSun-Gyoo Park
Sun-Gyoo Park
NKNae-Gyu Kang
Nae-Gyu Kang
Microneedles have emerged as a novel transdermal delivery tool that enables the delivery of various products such as drugs, vaccines, or cosmetic ingredients. Although the demand for solid microneedles composed of biocompatible polymer is increasing, the manufacture of microneedles using poly-lactic acid (PLA) with rapid drug-releasing is yet to be established and the process is still in its infancy. Here, we propose a novel strategy for the fabrication of PLA solid microneedles which enable a drug to be burst-released based on a solvent-casting process. This approach offers extreme simplicity, broad geometric capability, cost-effectiveness, and scalability based on high fidelity-replicas. It was verified that microneedles of various heights (250–500 μm) could be fabricated with appropriate mechanical strength to penetrate the stratum corneum layer of skin. By adding sugar in the composition of PLA microneedle, it was observed that both hydrophilic and hydrophobic drugs can be rapidly released within 30 min. Our burst drug-releasing PLA microneedle having both characteristics of solid microneedle and soluble microneedle and its fabrication approach based on solvent-casting will contribute to getting microneedle technology close to commercialization and beyond existing technical limitations.

24 May 2018 in Bulletin of the Korean Chemical Society
Verified
Journal Article
Closed access
PDF file
WSWoo Sun Shim
Woo Sun Shim
YHYoung Min Hwang
Young Min Hwang
SPSun Gyoo Park
Sun Gyoo Park
CLCheon Koo Lee
Cheon Koo Lee
NKNae-Gyu Kang
Nae-Gyu Kang

2 September 2020 in Molecules
Verified
Journal Article
Open access
PDF file
JKJaeyoon Kim
Jaeyoon Kim
SKSoon Re Kim
Soon Re Kim
YCYun-Ho Choi
Yun-Ho Choi
JSJae Young Shin
Jae Young Shin
CKChang-Deok Kim
Chang-Deok Kim
SLSanghwa Lee
Sanghwa Lee
The present study aimed to investigate the molecular mechanism of quercitrin, a major constituent of Hottuynia cordata extract, for its hair growth stimulating activities in cultured human dermal papilla cells (hDPCs). Quercitrin enhanced the cell viability and cellular energy metabolism in cultured hDPCs by stimulating the production of NAD(P)H and mitochondrial membrane potential (ΔΨ). The expression of Bcl2, an essential marker for anagen hair follicle and cell survival, was increased by quercitrin treatment. Quercitrin also increased the cell proliferation marker Ki67. The expression of growth factors—such as bFGF, KGF, PDGF-AA, and VEGF—were increased by quercitrin both in mRNA and protein levels. In addition, quercitrin was found to increase the phosphorylation of Akt, Erk, and CREB in cultured hDPCs, while inhibitors of MAPKs reversed the effects of quercitrin. Finally, quercitrin stimulated hair shaft growth in cultured human hair follicles. Our data obtained from present study are in line with those previously reported and demonstrate that quercitrin is (one of) the active compound(s) of Hottuynia cordata extract which showed hair growth promoting effects. It is strongly suggested that the hair growth stimulating activity of quercitrin was exerted by enhancing the cellular energy metabolism, increasing the production of growth factors via activation of MAPK/CREB signaling pathway.

Verified
Journal Article
Open access
PDF file
JSJae Young Shin
Jae Young Shin
JKJaeyoon Kim
Jaeyoon Kim
YCYun-Ho Choi
Yun-Ho Choi
NKNae-Gyu Kang
Nae-Gyu Kang
SLSanghwa Lee
Sanghwa Lee
Dexpanthenol (D-panthenol) is a precursor of vitamin B5 (pantothenic acid) and is widely used for dietary supplements and topical applications. D-panthenol has long been used in hair care products for the purpose of anti-hair loss, its effects and the underlying mechanisms, however, were barely reported. In this study, the effects of D-panthenol on human hair follicle cells, including dermal papilla cells (hDPCs) and outer root sheath cells (hORSCs), were investigated. D-panthenol enhanced the cell viability, increasing the cellular proliferation marker Ki67 in cultured hDPCs. The markers for apoptosis (Caspase3/9) and cell senescence (p21/p16), reported to be expressed in aged or resting phase follicles, were significantly reduced by D-panthenol. Anagen-inducing factors (ALP; β-catenin; versican), which trigger or elongate the anagen phase, were stimulated by D-panthenol. On the other hand, D-panthenol reduced TGF-β1 expressions in both mRNA and protein levels. The expression of VEGF, which is important for peripheral blood vessel activation; was up-regulated by D-panthenol treatment. In cultured hORSCs, cell proliferation and viability were enhanced, while the mRNA expression of cell senescence markers (p21/p16) was significantly down-regulated. The expressions of both VEGF and its receptor (VEGFR) were up-regulated by D-panthenol. In conclusion, our data suggest that the hair growth stimulating activity of D-panthenol was exerted by increasing the cell viability, suppressing the apoptotic markers, and elongating the anagen phase in hair follicles.

1 November 2014 in Journal of Biomedical Optics
Verified
Journal Article
Closed access
PDF file
HJHun-Jae Jang
Hun-Jae Jang
EHEugene Hur
Eugene Hur
YKYoonkwan Kim
Yoonkwan Kim
SLSeol-Hoon Lee
Seol-Hoon Lee
NKNae-Gyu Kang
Nae-Gyu Kang
JYJack J. Yoh
Jack J. Yoh
A breakthrough in the efficient transdermal delivery of drug via the laser-driven microjet is reported. A single source of laser beam is split into two: one beam ablates a targeted spot on a skin and another beam drives the injector for fast microjet ejection into a preablated spot. This combined ablation and microjet injection scheme using a beam splitter utilizes 1∶4 laser energy sharing between generation of the microhole via ablation and the microjet which is generated using the Er:YAG laser beam at a 2940-nm wavelength and 150-μs pulse duration. A careful analysis of the injection mechanism is carried out by studying the response of the elastic membrane that separates a driving water unit for bubble expansion from a drug unit for a microjet ejection. The efficiency of the present delivery scheme is evaluated by the abdominal porcine skin test using the fluorescein isothiocyanate staining and the confocal microscopy for quantitative delivery confirmation. The depth of penetration and the injected volume of the drug are also confirmed by polyacrylamide gel tests.